| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Epithelial-mesenchymal transition in cancer development and its clinical significance.
|
Cancer Sci
|
2009
|
3.39
|
|
2
|
A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases.
|
Ann Surg Oncol
|
2008
|
2.32
|
|
3
|
MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab.
|
Clin Cancer Res
|
2011
|
1.66
|
|
4
|
Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance.
|
Int J Cancer
|
2010
|
1.49
|
|
5
|
Significance of Lgr5(+ve) cancer stem cells in the colon and rectum.
|
Ann Surg Oncol
|
2010
|
1.47
|
|
6
|
Serum matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer.
|
Ann Surg Oncol
|
2010
|
1.40
|
|
7
|
MicroRNA miR-125b is a prognostic marker in human colorectal cancer.
|
Int J Oncol
|
2011
|
1.34
|
|
8
|
Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.
|
Carcinogenesis
|
2012
|
1.33
|
|
9
|
FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma.
|
Ann Surg Oncol
|
2010
|
1.06
|
|
10
|
Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer.
|
Carcinogenesis
|
2013
|
1.05
|
|
11
|
Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer.
|
Int J Cancer
|
2009
|
1.02
|
|
12
|
Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma.
|
Cancer Sci
|
2014
|
1.01
|
|
13
|
STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma.
|
Ann Surg Oncol
|
2010
|
0.97
|
|
14
|
Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.
|
Int J Oncol
|
2011
|
0.96
|
|
15
|
The clinical significance of vimentin-expressing gastric cancer cells in bone marrow.
|
Ann Surg Oncol
|
2010
|
0.95
|
|
16
|
Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer.
|
Anticancer Res
|
2014
|
0.93
|
|
17
|
A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.
|
J Surg Oncol
|
2009
|
0.91
|
|
18
|
Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis.
|
Cancer Sci
|
2013
|
0.90
|
|
19
|
TNFAIP8 overexpression: clinical relevance to esophageal squamous cell carcinoma.
|
Ann Surg Oncol
|
2011
|
0.89
|
|
20
|
Treatment of multiple liver metastasis from gastric carcinoma.
|
World J Surg Oncol
|
2007
|
0.89
|
|
21
|
CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma.
|
Oncol Rep
|
2012
|
0.88
|
|
22
|
[Primary esophageal motility disorders; especially about esophageal achalasia].
|
Kyobu Geka
|
2011
|
0.85
|
|
23
|
Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells.
|
Ann Surg Oncol
|
2013
|
0.84
|
|
24
|
Management of Barrett's esophageal carcinoma.
|
Surg Today
|
2013
|
0.84
|
|
25
|
Significance of INHBA expression in human colorectal cancer.
|
Oncol Rep
|
2013
|
0.83
|
|
26
|
Clinical significance of total colonoscopy for screening of colon lesions in patients with esophageal cancer.
|
Anticancer Res
|
2013
|
0.81
|
|
27
|
A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
|
J Surg Oncol
|
2014
|
0.81
|
|
28
|
Perioperative nutriture in esophageal cancer patients undergoing esophagectomy.
|
Hepatogastroenterology
|
2013
|
0.80
|
|
29
|
Clinical significance of human kallikrein7 gene expression in colorectal cancer.
|
Ann Surg Oncol
|
2010
|
0.78
|
|
30
|
Overexpression of SUGT1 in human colorectal cancer and its clinicopathological significance.
|
Int J Oncol
|
2010
|
0.78
|
|
31
|
Ghrelin level and body weight loss after esophagectomy for esophageal cancer.
|
J Surg Res
|
2011
|
0.78
|
|
32
|
[Re-thoracotomy for intrathoracic complications after esophagectomy for esophageal cancer].
|
Kyobu Geka
|
2013
|
0.77
|
|
33
|
Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
|
Cancer Chemother Pharmacol
|
2014
|
0.76
|
|
34
|
Expression of receptor tyrosine kinases in esophageal carcinosarcoma.
|
Oncol Rep
|
2013
|
0.76
|
|
35
|
Esophageal squamous cell carcinoma with marked eosinophil infiltration.
|
Case Rep Gastroenterol
|
2011
|
0.76
|
|
36
|
Important matters to identify robust markers for metastasis and recurrence in solid cancer.
|
Ann Surg Oncol
|
2009
|
0.75
|
|
37
|
18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients.
|
Dig Surg
|
2017
|
0.75
|
|
38
|
Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.75
|
|
39
|
Novel procedure of circular stapler-guided nasogastric tube insertion during esophageal reconstruction.
|
J Am Coll Surg
|
2011
|
0.75
|
|
40
|
Surgical treatment for nonspecific esophageal motility disorders.
|
Surg Today
|
2012
|
0.75
|
|
41
|
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
|
Hepatogastroenterology
|
2015
|
0.75
|
|
42
|
L-[3-18F]-α-methyltyrosine accumulation as a definitive chemoradiotherapy response predictor in patients with esophageal cancer.
|
Anticancer Res
|
2014
|
0.75
|